Michelle DoigPartner at Omega Funds
Michelle joined Omega Funds in 2016 as a Partner and Head of Corporate Development. She has 20 years of experience advising life sciences companies on private placements, public equity financing and M&A transactions. Previously, Michelle was at Third Rock Ventures, where she supported numerous portfolio companies including Allena, Blueprint, Global Blood Therapeutics, Jounce, Neon, MyoKardia and Sage. Prior to joining Third Rock, Michelle was Principal, Corporate Finance, at Abingworth. She was also a life sciences investment banker with Morgan Stanley in Toronto and New York; JP Morgan/H&Q in New York; and Lehman Brothers International in London. As a Banker, Michelle executed more than 40 equity and convertible transactions and numerous IPOs, private placements and M&A transactions for companies, including Gilead, MedImmune, Millennium, Illumina and Sepracor. Michelle graduated with an Honor’s degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario in London, Ontario.